ADENOCARD Drug Patent Profile
✉ Email this page to a colleague
When do Adenocard patents expire, and what generic alternatives are available?
Adenocard is a drug marketed by Astellas and is included in one NDA.
The generic ingredient in ADENOCARD is adenosine. There are twenty-six drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the adenosine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Adenocard
A generic version of ADENOCARD was approved as adenosine by HIKMA on June 16th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ADENOCARD?
- What are the global sales for ADENOCARD?
- What is Average Wholesale Price for ADENOCARD?
Summary for ADENOCARD
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 161 |
| Clinical Trials: | 4 |
| Patent Applications: | 3,036 |
| Drug Prices: | Drug price information for ADENOCARD |
| What excipients (inactive ingredients) are in ADENOCARD? | ADENOCARD excipients list |
| DailyMed Link: | ADENOCARD at DailyMed |
Recent Clinical Trials for ADENOCARD
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Colorado State University | Early Phase 1 |
| University of Utah | Early Phase 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | Early Phase 1 |
US Patents and Regulatory Information for ADENOCARD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas | ADENOCARD | adenosine | INJECTABLE;INJECTION | 019937-002 | Oct 30, 1989 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
